NOVA.F - Novo Nordisk A/S

Frankfurt - Frankfurt Delayed Price. Currency in EUR
51.00
-0.50 (-0.97%)
At close: 4:33PM CET
Stock chart is not supported by your current browser
Previous Close51.50
Open52.00
Bid51.50 x 100000
Ask52.00 x 100000
Day's Range51.00 - 52.00
52 Week Range38.00 - 53.00
Volume208
Avg. Volume229
Market Cap121.374B
Beta (3Y Monthly)0.61
PE Ratio (TTM)20.71
EPS (TTM)2.46
Earnings DateN/A
Forward Dividend & Yield1.10 (2.13%)
Ex-Dividend Date2019-08-16
1y Target EstN/A
  • Why this diabetes patient fears a no-deal Brexit
    Reuters Videos

    Why this diabetes patient fears a no-deal Brexit

    Her daily routine is a matter of life and death for Georgina. She is one of Britain's one million diabetics now facing the possibility of medical shortages if the UK plunges out of the European Union without a deal at the end of October. (SOUNDBITE) (English) LONDON RESIDENT AND DIABETES PATIENT, GEORGINA, SAYING: "I can't tell you how worried I am about that. It's life-threatening for me." Her fears have been exacerbated by the British government's own planning for a worst case scenario. The Yellowhammer document suggests the important Calais to Dover trade route could face months of disruption, and the pharmaceuticals industry is particularly vulnerable. That's because three quarters of the 37 million packs of drugs imported from Europe each month, come through the short straits route. Georgina is concerned that the medical supplies she depends on could dwindle. She tests her blood sugar levels four times a day to work out how much of an insulin boost she needs at meal times, in addition to a pump that gives her a low level dosage of insulin 24 hours a day. (SOUNDBITE) (English) LONDON RESIDENT AND DIABETES PATIENT, GEORGINA, SAYING: "I can live without the pump and I can live without all the bits and pieces that go with the pump but I cannot live without the blood testing strips because that's just as important, nearly as important, as having an adequate insulin supply. And the two really go so hand in hand, that's the one thing I don't think people realize." She may take some comfort from private sector preparations. (SOUNDBITE) (English) GENERAL MANAGER OF NOVO NORDISK UK, PINDER SAHOTA, SAYING: "At Novo Nordisk we've been preparing for the last three years, if not more than that, for the worst-case scenario." Pinder Sahota is the UK general manager of the world's biggest insulin maker, Novo Nordisk. (SOUNDBITE) (English) GENERAL MANAGER OF NOVO NORDISK UK, PINDER SAHOTA, SAYING: "So what we've done is we've increased our stock level from - a normal average of stock-holding is six weeks, we've increased that to 18 weeks." That's a warehouse capacity of 3.8 million packs of insulin. Piled up - they'd stand 12 times the height of London's Shard skyscraper. Novo Nordisk has also reserved spaces on alternate ferry routes and air freight if required while exploring other factors such as what to do in the event of fuel shortages. (SOUNDBITE) (English) GENERAL MANAGER OF NOVO NORDISK UK, PINDER SAHOTA, SAYING: "Whilst we can control what we can control, it's the uncertainties of how long will the delays be, that are factors outside our control. But we're doing everything we can to ensure that the patients can continue to get the medicines that they need." But the situation is increasing tensions between industry and the government - and not just around the intricacies of planning for a no-deal. Hugo Fry, UK managing director of France's Sanofi, also says that patients have to be prioritized. (SOUNDBITE) (English) MANAGING DIRECTOR OF SANOFI UK, HUGO FRY, SAYING: "Of course, we're starting to ask ourselves the question... although we're happy to do it, it is starting to weigh on our balance sheet, on our logistics, keeping all this additional stock in the country." And that leads to another frustration - that while the companies like Sanofi and Novo Nordisk dedicate huge resources to such preparation, they are having to spend less time on their normal job - bringing innovative drugs to market.

  • Livongo Bounces Back After Revenue Guidance Boost
    GuruFocus.com

    Livongo Bounces Back After Revenue Guidance Boost

    Analysts set average 12-month target more than 70% above current price Continue reading...

  • Barrons.com

    Novo Nordisk’s Shares Are Rising Because Newer Diabetes Drugs Are Selling Well

    Newer insulin drugs did some heavy lifting for the company. Around half of the Danish company’s global sales are generated in the U.S., where diabetes and obesity are major health issues. More than 100 million Americans have diabetes or prediabetes and the cost of a single vial of insulin can run into hundreds of dollars, even with insurance.

  • Reuters

    UPDATE 2-Novo Nordisk nudges up 2019 sales outlook as new drugs excel

    Novo Nordisk posted third-quarter operating profit a touch below expectations on Friday on weak insulin sales and impairments, but nudged up its sales outlook on hopes for new type 2 diabetes and obesity drugs. Novo now sees 2019 sales growth at 5-6% versus 4-6% previously, and held its forecast for operating profit growth at 4-6%, both in local currency terms. The world's largest maker of diabetes drugs is betting on new treatments, including a first-of-its-kind tablet, to offset pricing pressure from competing insulins and U.S. lawmakers, who have been critical of rising drug costs.

  • Novo Nordisk nudges up 2019 sales outlook as new drugs excel
    Reuters

    Novo Nordisk nudges up 2019 sales outlook as new drugs excel

    Novo Nordisk posted third-quarter operating profit a touch below expectations on Friday on weak insulin sales and impairments, but nudged up its sales outlook on hopes for new type 2 diabetes and obesity drugs. Novo now sees 2019 sales growth at 5-6% versus 4-6% previously, and held its forecast for operating profit growth at 4-6%, both in local currency terms. The world's largest maker of diabetes drugs is betting on new treatments, including a first-of-its-kind tablet, to offset pricing pressure from competing insulins and U.S. lawmakers, who have been critical of rising drug costs.

  • Can Novo Nordisk A/S's (CPH:NOVO B) ROE Continue To Surpass The Industry Average?
    Simply Wall St.

    Can Novo Nordisk A/S's (CPH:NOVO B) ROE Continue To Surpass The Industry Average?

    While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

  • 7 Safe Stocks to Buy and Hold Through 2020
    InvestorPlace

    7 Safe Stocks to Buy and Hold Through 2020

    The winter holiday season is kicking into high gear now. With that in mind, it's time to start positioning your portfolio for 2020. It's a great time to cut loose some stocks that have stopped working and redeploy the capital elsewhere. Tax-loss selling in particular can make for a great time to jettison some old positions and pick up more promising stocks to buy going forward.And now, as 2019 winds to a close, it's time to start thinking about more defensive stocks. Over the past two months we've seen a clear rotation out of pure growth stocks into more value-oriented names. Particularly with the move in interest rates, investors will demand safe income-paying stocks to buy in 2020. Here's seven safe stocks that should be great buy-and-hold candidates for at least the next year. Stocks to Buy: Altria (MO)Source: Kristi Blokhin / Shutterstock.com Dividend Yield: 7.6%InvestorPlace - Stock Market News, Stock Advice & Trading TipsIt appears that the bottom may be in for the tobacco stocks. The sector has rallied sharply since I highlighted it recently. As these things tend to do, it appears the general media scare around vaping illnesses is starting to taper off. Additionally, more and more focus is going to the vaping of THC, often in illicit cartridges. Very few of the reported lung problems so far have been tied to Juul or other credible regulated nicotine suppliers.This doesn't mean Juul's problems will go away overnight. In the long run, however, I expect Altria (NYSE:MO) to make money on its vaping investment. That's in sharp contrast to the market, which has recently been pricing MO stock as if the company will need to write off the full investment entirely.As it is, Altria's existing cigarette sales along with cash flow from its stake in Anheuser-Busch (NYSE:BUD) is enough to cover the dividend. If and when Juul starts providing meaningful cash flow to Altria, it will support a higher share price and dividend -- but you don't need to justify the current $46 MO stock price and greater than 7% dividend yield. Over the long haul, tobacco companies have continued to make tremendous amounts of cash flow despite considerable regulatory intervention and downright hostile media coverage. * 10 Hot Pot Stocks to Buy Vaping worries will pass sooner or later; the desire to consume nicotine, however, isn't going anywhere. By the end of 2020, people that bought Altria when it was cheap will be enjoying their dividends with the vaping scare already long forgotten. Wells Fargo (WFC)Source: Ken Wolter / Shutterstock.com Dividend Yield: 4.1%It's almost unbelievable that Wells Fargo (NYSE:WFC) stock remains this much of a value. The company has announced all sorts of good news this year, but the share price hasn't gone anywhere yet.The company brought in a highly credible new CEO in the form of Charles Scharf, the former head of Bank of New York Mellon (NYSE:BK) and Visa (NYSE:V). Those are two of the largest and most reputable financial firms in the country. Wells Fargo's critics had slammed the company, saying management was untrustworthy and that the company couldn't attract a competent outsider CEO. The board proved them wrong and brought in a superstar new chief executive. Scharf's particular competence in financial technology matters will assist Wells Fargo greatly.WFC's earnings have also come in stronger than expected. People have been slamming the bank stocks all year. As interest rates have dropped, people are afraid of what will happen to banks' profit margins. Yet Wells Fargo's diversified business has continued to generate steady earnings despite the net interest margin headwind.That point, combined with the company's excess capital position, leads to the dividend. Since the 2008-2009 financial crisis, companies have stockpiled capital in response to regulatory demands. Capital levels reached historically extreme levels, in fact. Now the regulators are starting to loosen up a bit, and that is letting the banks put money back to work. Wells Fargo is doing so with both a double-digit dividend increase this year and a massive share buyback. Management intends to repurchase more than 10% of all outstanding WFC stock over the next year. With the company paying an over 4% dividend and providing a massive persistent bid under the share price with the buyback, Wells Fargo is a great safe stock holding for 2020. Johnson & Johnson (JNJ)Source: Alexander Tolstykh / Shutterstock.com Dividend Yield: 3%Johnson & Johnson (NYSE:JNJ) isn't the most exciting stock on this list by any means. But it is one of the safest. In fact, the company has been a bedrock of conservative portfolios for an entire century now. And nothing has changed. The company remains well-diversified with business operations spanning prescription drugs, consumer health and hygiene products, and medical devices.J&J runs as a decentralized firm, giving each unit independent management and operating authority. This creates a high level of resilience, as Johnson and Johnson has always been able to offset weakness from any one division or product with strength in others. Now, for example, the company is seeing weakness in consumer products but strength elsewhere has balanced it out.Why JNJ stock for 2020 in particular? Recently, the company has been dinged by lawsuits for both its involvement in the opioid crisis and various other matters. It just got hit with another scare this past week, as JNJ stock slumped on news of a baby powder recall. However, some folks tend to trade the headline and not think about the longer-term impact. Generally, J&J is able to get fines reduced greatly on appeal, and despite many decades of making sometimes controversial healthcare products, it has rarely gotten stung with true shareholder-value destroying liabilities. * 10 Stocks to Sell Before December's Meltdown With JNJ stock down 20% from its highs despite a strong rally in defensive stocks, there's a great argument for locking in the stock's rock-solid dividend for 2020, along with a potential run-up in the share price to $150 as lawsuit fears diminish. Dow (DOW)Source: JHVEPhoto / Shutterstock.com Dividend Yield: 5.9%Dow (NYSE:DOW) is not the safest company on this list. There's generally a trade-off between dividend yield and safety of said dividend. But at least through the end of 2020, Dow should be able to maintain its current dividend level, offering shareholders an almost 6% yield. And the stock price could appreciate nicely as current recession fears and worries about the chemical market recede.Simply put, Dow is a high-yield company that also faces significant potential trade war disruption. Throw in all the confusion around the recent spinoff, and investors don't quite know what to make of the new DOW stock. My take, at least through the end of 2020, is to look for a safe 6% dividend yield and the possibility of some nice share price upside if global economic sentiment improves.Already, we've seen some significant improvement on the economic front. Not only does data keep coming in reasonably strong, now the yield curve has reverted to normal. Remember everyone panicking over the yield curve inversion a few months ago? That's gone now. A company like Dow wins the most as the economic tide rises again. At 11 times forward earnings, DOW stock is a bargain too. Public Storage (PSA)Source: Ken Wolter / Shutterstock.com Dividend Yield: 3.3%Looking to park some money away for safekeeping at a higher interest rate than you'd get at the bank? Why not consider stowing it at Public Storage (NYSE:PSA)? Real estate investment trusts have been hard stocks to buy lately -- the sector has soared to new all-time highs as investors hunt for yield. This has made valuations extremely expensive for real estate stocks in general.Due to concerns about pricing and capacity in the self-storage space, REITs like Public Storage have trailed their peers to an extent. PSA stock is up nicely this year, but it's still well short of its all-time highs, at least for the time being. * 7 Beverage Stocks to Buy Now That could change in 2020 though. New self-storage site building has slowed down dramatically. Meanwhile, the industry remains fragmented with mom-and-pop operators holding a major portion of the business. This gives Public Storage the opportunity to keep using its industry-best balance sheet to pick up properties opportunistically and create additional growth. And at worst, PSA stock would tread water, safely kicking out its rock-solid dividend as Americans continue to store their belongings, regardless of the economic winds. Walgreens (WBA)Source: saaton / Shutterstock.com Dividend Yield: 3.3%Walgreens (NASDAQ:WBA) is having a bad year. And this bad year comes on top of a series of mediocre ones. Dating back to 2013, WBA stock has been merely flat during a raging bull market. Don't bet against Walgreens forever though. In fact, 2020 could be the rebound year for WBA stock.You may not know Walgreens as a safe conservative stock play. Historically, Walgreens has had a surging share price, and as a result, a relatively low dividend yield. Things have changed though. With the prolonged stagnation in the share price, Walgreens' dividend yield has now moved up to 3.3%.That's in large part because Walgreens' earnings continue to grow, and it pays a higher and higher dividend with every passing year. In fact, it's a dividend aristocrat stock with more than 25 years of consecutive dividend hikes.There are long-term concerns about the company's business model. Drug pricing is a question mark, and investors fear that Walgreens will earn lower profit margins on prescriptions in the future. Meanwhile, front-of-the-store sales of convenience goods such as soda and candy may be pressured due to the changing retail climate. Still, Walgreens has proved resilient over the decades and any sort of political clarity on drug pricing in 2020 as the election plays out could send WBA stock sharply higher. In the meantime, enjoy the stock's highest dividend yield in ages. Novo Nordisk (NVO)Source: joreks / Shutterstock.com Dividend Yield: 1.2%If you're a newer investor, you may not have heard of Novo Nordisk (NYSE:NVO). You've certainly heard about its products though. Novo is the world's leader in producing insulin and other therapies for diabetes. As the diabetes public health crisis continues to worsen both in the U.S. and abroad, Novo's importance in the global healthcare system increases with every passing year.Short of some massive dietary and lifestyle changes, it's hard to imagine a world in which the rate of diabetes declines significantly in coming years, given current demographic trends. This, in turn, will ensure that Novo Nordisk has much work to do.NVO stock is still down significantly from its all-time highs. There was a major concern about insulin pricing a couple years ago, and even with that largely resolved, shares aren't back to their peak -- yet. The company just picked up a huge regulatory approval, adding a specific catalyst to the company's already powerful demographic tailwinds. Novo pays a steadily rising dividend (as measured in its home currency, Danish Kroner) and should enjoy a significant share price increase in 2020 as well, making it a perfect growth and income opportunity in a defensive safe stock.At the time of this writing, Ian Bezek owned DOW, JNJ, MO, NVO, PSA, WBA and WFC stock. You can reach him on Twitter at @irbezek. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 REITs With Big Dividend Raises Coming * 10 Hot Pot Stocks to Buy * 5 Hot Stocks That Have Gone Ice Cold The post 7 Safe Stocks to Buy and Hold Through 2020 appeared first on InvestorPlace.

  • New Sanofi CEO Looks to Shake Things Up
    GuruFocus.com

    New Sanofi CEO Looks to Shake Things Up

    Paul Hudson is examining the organization from top to bottom with the goal of developing a strategy to put the company on the road to success Continue reading...

  • Is Novo Nordisk A/S  (NVO) A Good Stock To Buy?
    Insider Monkey

    Is Novo Nordisk A/S (NVO) A Good Stock To Buy?

    Is Novo Nordisk A/S (NYSE:NVO) a good bet right now? We like to analyze hedge fund sentiment before conducting days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […]

  • 5 European Health Care Companies With High Business Quality
    GuruFocus.com

    5 European Health Care Companies With High Business Quality

    European markets offer opportunities as investors await US-China trade talks Continue reading...

  • An Intrinsic Calculation For Novo Nordisk A/S (CPH:NOVO B) Suggests It's 25% Undervalued
    Simply Wall St.

    An Intrinsic Calculation For Novo Nordisk A/S (CPH:NOVO B) Suggests It's 25% Undervalued

    Does the October share price for Novo Nordisk A/S (CPH:NOVO B) reflect what it's really worth? Today, we will estimate...

  • 4 High-Quality US Stocks as Trade War Fears Are Rekindled
    GuruFocus.com

    4 High-Quality US Stocks as Trade War Fears Are Rekindled

    Top Berkshire holding Apple makes list Continue reading...

  • Benzinga

    Cool Chain Association Calls For Data Sharing

    Cool chain partners are changing their mindsets to join shippers and start-ups shaping the supply chain of the future, according to speakers at the recent Cool Chain Association's (CCA) pharma and biosciences conference in Paris. Conference delegates also heard that the air cargo industry could make a difference in final mile delivery that could save the lives of infants. The CCA, which hosts two regular events each year, one on pharma and one on perishables, brings together industry leaders from across the cool chain to network.

  • GuruFocus.com

    Foreign Firms Recognized as Hottest Biotechs

    For the first time since FierceBiotech issued its list, companies outside the US are included Continue reading...

  • How Novo Nordisk Is Aiming To Take A Slice Of Lilly's Diabetes Market
    Investor's Business Daily

    How Novo Nordisk Is Aiming To Take A Slice Of Lilly's Diabetes Market

    Novo Nordisk's newest diabetes treatment, an oral drug called Rybelsus, won't immediately gouge another medicine from pharmaceutical company Eli Lilly. Both are GLP-1 receptor agonists.

  • Reuters

    Novo Nordisk targets bigger slice of diabetes market with new tablet

    Danish drugmaker Novo Nordisk is aiming for a big slice of the multibillion-dollar diabetes market with a new pill, approved by U.S. authorities on Friday, that caters for patients with an aversion to needles. The company built its position as the world's biggest insulin maker on the back of injectable drugs, but now aims to transform the market with a first-of-its-kind tablet version of its semaglutide drug. While more than 70% of diabetes prescriptions in the United States are already for oral treatments, none of these are from the GLP-1 class that Novo specialises in, and which are viewed as highly effective medicines that stimulate insulin production.

  • UPDATE 2-Novo Nordisk wins U.S. approval for first-of-its-kind oral diabetes drug
    Reuters

    UPDATE 2-Novo Nordisk wins U.S. approval for first-of-its-kind oral diabetes drug

    The U.S. Food and Drug Administration on Friday approved an oral version of Novo Nordisk's diabetes drug semaglutide, a boost for the Danish drugmaker which hopes to transform the market by offering patients a non-injectable treatment. The world's biggest producer of diabetes drugs already sells an injectable once-weekly version of semaglutide under the brand name Ozempic at nearly $800 per month. Novo did not disclose what it plans to charge for the new oral treatment, called Rybelsus, but said it would be "competitively priced" with other drugs in the same "GLP-1" class of medicines.

  • How This Pharma Stock Could Knock Eli Lilly Off Its Diabetes Pedestal
    Investor's Business Daily

    How This Pharma Stock Could Knock Eli Lilly Off Its Diabetes Pedestal

    Novo Nordisk stock popped Tuesday after an analyst suggested the pharmaceutical company's oral diabetes treatment, semaglutide, could swipe share from Eli Lilly's rival drug, Trulicity.

  • Reuters

    Factbox: Britain's insulin providers prepare for Brexit fallout

    With Britain sourcing the vast majority of the insulin needed by its 1 million diabetics from overseas, its biggest providers have had to restructure their supply chains in case a chaotic Brexit disrupts the normal arteries of trade. Below are some of the steps Novo Nordisk, Eli Lilly and Sanofi have taken to prepare for Britain's departure from the European Union on Oct. 31. - All three firms have increased the amount of insulin they are holding inside the country in case a no-deal Brexit leads to customs checks and lengthy delays at Britain's biggest ports of Dover and Folkestone.

  • Reuters

    With a backup to the backup, insulin makers say they're primed for Brexit

    For two men trained as scientists, the bosses of Britain's major insulin providers have had to become experts in ferry schedules, trucking laws and warehouse capacity as they seek to guarantee the supply of life-saving drugs through a chaotic Brexit. With Britain set to leave the European Union within weeks, Pinder Sahota at the world's biggest insulin maker Novo Nordisk, and Sanofi's Hugo Fry have rebuilt operations to withstand the most turbulent of events.

  • Benzinga

    The Week Ahead In Biotech: Novo Nordisk And Merck Await FDA Rulings, 2 IPOs On Deck

    Biotech stocks rebounded in last week after declining modestly in the previous week. Some of the drugs that cleared the FDA hurdle this week include Ardelyx Inc (NASDAQ: ARDX )'s constipation drug Ibsrela; ...

  • Reuters

    UPDATE 1-Novo Nordisk to cut insulin prices in the U.S.

    Novo Nordisk will offer cheaper insulin to U.S. diabetics, the Danish drugmaker said on Friday, in response to criticism over the high price of the medication and after similar moves by rivals Sanofi and Eli Lilly. President Donald Trump has made high prescription drug prices a top issue in the 2016 presidential campaign and said that drug companies were "getting away with murder". Novo will offer a generic version of its most heavily prescribed insulin drug Novolog, used by about a million U.S. patients, at a 50% discount compared to the current list price, the company said in a statement.